

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: : Examiner:
Mark Edward Bunnage, et al. : To Be Assigned

APPLICATION NO.: To Be Assigned : Group Art Unit: To Be Assigned

FILING DATE: Herewith :

TITLE: Pyrazolopyrimidinones Which Inhibit Type 5 Cyclic :
Guanosine 3',5'-Monophosphate Phosphodiesterase
(cGMP-PDE5) For The Treatment of Sexual
Dysfunction :
.....

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date: MARCH 23, 2004

James J. Jones
James J. Jones
Attorney for Applicant(s)
Reg. No. 30,561

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-4903

EXPRESS MAIL NO. EV 271824876 US

| | | |
|--|------------------------------------|----------------------------------|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | ATTY. DOCKET NO. PC9430BJTJ | SERIAL NO. To Be Assigned |
| APPLICANT Mark E. Bunnage, et al. | | |
| FILING DATE Herewith | | GROUP To Be Assigned |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | | | | | | | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
|---------------------|--|-----------------|---|---|---|---|---|---|-------------|---------------|-------|----------|-------------------------------|
| | | | | | | | | | | | | | |
| | | 5 | 4 | 2 | 6 | 1 | 0 | 7 | 20 June 95 | Bell et al. | 514 | 234.2 | |
| | | 5 | 3 | 4 | 6 | 9 | 0 | 1 | 13 Sept 94 | Bell et al. | 514 | 258 | |
| | | 5 | 7 | 1 | 9 | 2 | 8 | 3 | 17 Feb 98 | Bell et al. | 544 | 262 | |
| | | 5 | 7 | 3 | 4 | 0 | 5 | 3 | 31 Mar 98 | Terrett | 544 | 277 | |
| | | 4 | 6 | 6 | 6 | 9 | 0 | 8 | 19 May 87 | Hamilton | 514 | 229 | |
| | | 4 | 6 | 6 | 3 | 3 | 2 | 6 | 5 May 87 | Hamilton | 514 | 258 | |
| | | 5 | 2 | 7 | 2 | 1 | 4 | 7 | 21 Dec 93 | Bell et al | 514 | 234.2 | |
| | | 3 | 9 | 9 | 2 | 4 | 4 | 1 | 16 Nov 76 | Helland | 260 | 518 | |
| | | 4 | 6 | 6 | 8 | 2 | 8 | 0 | 26 May 87 | Gehring et al | 71 | 92 | |
| | | 5 | 9 | 5 | 5 | 6 | 1 | 1 | 21 Sept 99 | Dunn et al | 544 | 262 | |
| | | 4 | 8 | 7 | 1 | 8 | 4 | 3 | 3 Oct 89 | Roger et al | 540 | 575 | |
| | | 5 | 2 | 9 | 4 | 6 | 1 | 2 | 15 March 94 | Bacon et al | 514 | 234.2 | |
| | | 5 | 7 | 3 | 6 | 5 | 4 | 8 | 7 April 98 | Baco et al | 514 | 258 | |
| | | 5 | 2 | 5 | 0 | 5 | 3 | 4 | 5 Oct 93 | Bell et al | 514 | 258 | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | | | | | | | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|---|---|---|---|---|---|-------------|---------------|-------|----------|-------------|----|
| | | | | | | | | | | | | | YES | NO |
| | WO | 9 | 9 | 5 | 4 | 3 | 3 | 3 | 28 Oct 99 | International | C07D | 487/04 | | |
| | WO | 9 | 6 | 1 | 6 | 6 | 5 | 7 | 6 June 96 | International | A61K | 31/505 | | |
| | WO | 9 | 4 | 0 | 0 | 4 | 5 | 3 | 6 Jan 94 | International | C07D | 473/30 | | |
| | WO | 9 | 4 | 0 | 5 | 6 | 6 | 1 | 17 Mar 94 | International | C07D | 471/04 | | |
| | WO | 9 | 3 | 1 | 2 | 0 | 9 | 5 | 24 June 93 | International | C07D | 239/91 | | |
| | WO | 9 | 3 | 0 | 7 | 1 | 4 | 9 | 15 April 93 | International | C07D | 487/04 | | |
| | WO | 9 | 3 | 0 | 6 | 1 | 0 | 4 | 1 April 93 | International | C07D | 487/04 | | |
| | WO | 9 | 6 | 2 | 8 | 4 | 2 | 9 | 19 Sept 96 | International | C07D | 239/70 | | |
| | WO | 9 | 6 | 2 | 8 | 4 | 4 | 8 | 19 Sept 96 | International | C07D | 487/04 | | |
| | EP | 0 | 3 | 4 | 9 | 2 | 3 | 9 | 16 Mar 94 | EPO | C07D | 487/04 | | |
| | EP | 0 | 6 | 3 | 6 | 6 | 2 | 6 | 1 Feb 95 | EPO | C07D | 487/04 | | |
| | WO | 9 | 4 | 2 | 8 | 9 | 0 | 2 | 22 Dec 94 | International | A61K | 31/505 | | |
| | WO | 9 | 6 | 1 | 6 | 6 | 4 | 4 | 6 June 1996 | International | A61K | 31/00 | | |
| | EP | 0 | 2 | 0 | 1 | 1 | 8 | 8 | 17 Dec 86 | EPO | C07D | 487/04 | | |

EXPRESS MAIL NO. EV271824876US

| | | | | | | | | | | | | | |
|--|--|--|--|--|--|--|--|--|--|----------------------------------|--|--|--|
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | | | | | ATTY. DOCKET NO. PC9430BJTJ | | | | SERIAL NO. To Be Assigned | | | |
| | | | | | | APPLICANT Mark E. Bunnage, et al. | | | | | | | |
| | | | | | | FILING DATE Herewith | | | | GROUP To Be Assigned | | | |

| | | | | | | | | | | | | | |
|----|---|---|---|---|---|---|---|-------------|---------------|------|--------|--|--|
| EP | 0 | 3 | 5 | 2 | 9 | 6 | 0 | 31 Jan 1990 | EPO | C07D | 31/52 | | |
| EP | 0 | 4 | 4 | 2 | 2 | 0 | 4 | 21 Aug 1991 | EPO | C07D | 487/04 | | |
| EP | 0 | 3 | 7 | 1 | 7 | 3 | 1 | 6 June 1990 | EPO | C07D | 239/91 | | |
| EP | 0 | 5 | 7 | 9 | 4 | 9 | 6 | 19 Jan 1994 | EPO | C07D | 401/04 | | |
| EP | 0 | 4 | 6 | 3 | 7 | 5 | 6 | 2 Jan 92 | EPO | C07D | 487/04 | | |
| EP | 0 | 5 | 2 | 6 | 0 | 0 | 4 | 7 Feb 1992 | EPO | C07D | 487/04 | | |
| WO | 9 | 9 | 6 | 4 | 0 | 0 | 4 | 16 Dec 1999 | International | A61K | 31/505 | | |
| WO | 9 | 8 | 4 | 9 | 1 | 6 | 6 | 5 Nov 1998 | International | C07D | 487/04 | | |
| WO | 9 | 9 | 6 | 4 | 0 | 0 | 4 | 16 Dec 99 | International | A61K | 31/505 | | |
| WO | 9 | 3 | 1 | 5 | 0 | 6 | 2 | 5 Aug 93 | International | C07D | 241/04 | | |

| | | | | | | | | | | | | | |
|---|--|--|--|--|--|--|--|--|--|--|--|--|--|
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | | | | | | | | | | |
| | | DuMaitre et al., J. Med. Chem. 39(8), 1996, 1635-1644 | | | | | | | | | | | |
| | | Bowman et al., Br. J. Pharmacol., 1984, 81(4), pg 665 | | | | | | | | | | | |
| | | Am. J. Physiol, 1993, 264(2), p H419 | | | | | | | | | | | |
| | | Rajfer et al., New Eng. J. Med., 1992, 326(2), pg 90 | | | | | | | | | | | |
| | | J. Urol., 1993, 149(4), pg 285A | | | | | | | | | | | |
| | | Murray, Drug News & Perspective, 1993, 6(23), pg 150 | | | | | | | | | | | |
| | | Sohn et al., Int. J. Imp. Res., 1992, 4(S2), pg 11 | | | | | | | | | | | |
| | | J. Urol., 1992, 147(S4), pg 454A | | | | | | | | | | | |
| | | Harriet W. Hamilton, et al., J. Med. Chem. 1987, 30, pgs 91-96 | | | | | | | | | | | |
| | | Czarniecki et al in Annual Reports in Medicinal Chemistry, 31, 61-70 | | | | | | | | | | | |
| | | Henze et al., J. Am. Chem. Soc., Feb, 1939, pgs 433-435 | | | | | | | | | | | |
| | | Terfort et al., J. Chem.. Soc, Perkin Trans. 1, 1996, pgs 1467-1479 | | | | | | | | | | | |

| | |
|-----------------|------------------------|
| EXAMINER | DATE CONSIDERED |
|-----------------|------------------------|

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.